NAGE
Niagen Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.99
−0.17%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- $0.01
- Revenue estimate
- $34.4M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- $0.01
- EPS estimate
- $0.01
- Revenue actual
- $29.8M
- Revenue estimate
- $30.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +34.2%
- Revenue beats (12Q)
- 5
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | $0.01 | $0.01 | Beat 20.05% | $29.8M |
| May 6, 2026 | $0.06 | $0.07 | Beat 16.67% | $31.5M |
| Mar 4, 2026 | $0.02 | $0.03 | Beat 50.00% | $33.8M |
| Mar 4, 2025 | $0.02 | $0.03 | Beat 50.00% | $29.1M |
| Oct 31, 2024 | $0.01 | $0.02 | Beat 100.00% | $25.6M |
| Jun 30, 2024 | -$0.02 | -$0.00 | Beat 99.00% | $22.7M |
| Mar 31, 2024 | -$0.02 | -$0.01 | Beat 67.30% | $22.2M |
| Dec 31, 2023 | -$0.02 | $0.00 | Beat 106.76% | $21.2M |
| Sep 30, 2023 | -$0.03 | -$0.01 | Beat 57.40% | $19.5M |
| Jun 30, 2023 | -$0.04 | -$0.03 | Beat 26.93% | $20.3M |
| Mar 31, 2023 | — | -$0.03 | — | $22.6M |
| Dec 31, 2022 | -$0.05 | -$0.02 | Beat 58.80% | $21.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026